Radioprotection: smart games with death
Open Access
- 1 July 2010
- journal article
- editorial
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 120 (7) , 2270-2273
Abstract
The efficacy of cancer treatment by radiation and chemotherapeutic drugs is often limited by severe side effects that primarily affect the hematopoietic system and the epithelium of the gastrointestinal tract. Progress in understanding differences in the mechanisms involved in the responses of normal and tumor cells to genotoxic stress has led to the development of new rational approaches to selective protection of normal cells, such as suppression of apoptosis by pharmacological inhibition of p53 or activation of NF-κB. Another promising approach presented in this issue by Johnson et al. is based on the idea of using pharmacological inhibitors of cyclin-dependent kinases (CDKs) to convert normal cells into a radioresistant state by inducing reversible cell cycle arrest at the G1/S transition. The evidence indicates that this approach is likely to be specific for protection of normal cells and may, therefore, have clinical potential as an adjuvant in anticancer therapies.Keywords
This publication has 21 references indexed in Scilit:
- Prospective therapeutic applications of p53 inhibitorsBiochemical and Biophysical Research Communications, 2005
- Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenograftsMolecular Cancer Therapeutics, 2004
- Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in miceOncogene, 2004
- Protection against ionizing radiation by antioxidant nutrients and phytochemicalsToxicology, 2003
- Short-term injection of antiapoptotic cytokine combinations soon after lethal γ-irradiation promotes survivalBlood, 2003
- Cyclin D-dependent kinases, INK4 inhibitors and cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2002
- Endothelial Apoptosis as the Primary Lesion Initiating Intestinal Radiation Damage in MiceScience, 2001
- A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer TherapyScience, 1999
- Transgenic mice with p53‐responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivoThe EMBO Journal, 1997
- Cell Kinetics and Radiation BiologyInternational Journal of Radiation Biology and Related Studies in Physics, Chemistry and Medicine, 1986